Breakthrough order from a leading academic medical center in the United States


 

Senzime's US subsidiary, Senzime Inc, has gradually expanded during the year and has recently completed its first stage of commercial development. The direct sales team as well as the companies two distributors are currently running evaluations across the US.

This initial order is a broad deployment of TetraGraph systems across the hospital operating rooms, starting with an order of 10 systems including TetraSens consumables, with the intention for further expansion to eliminate the incidence of residual neuromuscular blockade.

” Our US team works closely with their customers to facilitate implementation of our novel cutting-edge digital technology. Having their first evaluation materializing into a large sale is of course extremely encouraging. Objective monitoring is a game-changer when it comes to increasing patient safety in surgery, where 6 out of 10 patients experience residual neuromuscular blockade today”, says Pia Renaudin, CEO of Senzime.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com

       

TO THE EDITORS
About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on December 30, 2020, 14:45 CET.